Cardiovascular Systems Stock
€18.20
Your prediction
Financial data and news for Cardiovascular
sharewise wants to provide you with the best news and tools for Cardiovascular, so we directly link to the best financial data sources.
Financials
News
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
Key Points
- Interested in BioAge Labs, Inc.? Here are five stocks we like better.
- BioAge Labs said its lead drug BGE-102 is on track for near-term data in two areas: a Phase 2 cardiovascular
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
Johnson & Johnson’s (NYSE: JNJ) price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of

